公开(公告)号：US08080248B2

公开(公告)日：2011-12-20

申请号：US12780006

申请日：2010-05-14

Applicant: Allen Radin ,  Sean Stevens ,  Tammy T. Huang ,  Joel H. Martin ,  Jeanette L. Fairhurst ,  Ashique Rafique ,  Eric Smith ,  Kevin J. Pobursky ,  Nicholas J. Papadopoulos ,  James P. Fandl ,  Gang Chen ,  Margaret Karow

Inventor： Allen Radin ,  Sean Stevens ,  Tammy T. Huang ,  Joel H. Martin ,  Jeanette L. Fairhurst ,  Ashique Rafique ,  Eric Smith ,  Kevin J. Pobursky ,  Nicholas J. Papadopoulos ,  James P. Fandl ,  Gang Chen ,  Margaret Karow

IPC: A61K39/395

CPC classification number: A61K39/3955 ,  A61K31/4706 ,  A61K31/519 ,  A61K31/655 ,  A61K38/191 ,  A61K39/39541 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/248 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  Y10S514/885 ,  A61K2300/00

Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.

Abstract translation: 本发明提供使用特异性结合人白细胞介素-6受体（hIL-6R）的完全人抗体或其抗原结合片段预防或治疗类风湿性关节炎的方法。 本发明的方法可以包括施用第二治疗剂，例如非甾体抗炎药（NSAID），糖皮质激素，疾病缓解性抗风湿药（DMARD）中的一种或多种，​​或 TNF-α拮抗剂，T细胞阻断剂，抗CD20抗体，IL-1，JAK或IL-17拮抗剂或其任何组合。

公开(公告)号：US07361350B2

公开(公告)日：2008-04-22

申请号：US11056730

申请日：2005-02-11

Applicant: Scott Mellis ,  Neil Stahl ,  Allen Radin ,  Steven Weinstein ,  Denise Calaprice ,  Margaret Karow ,  Joanne Papadopoulos

Inventor： Scott Mellis ,  Neil Stahl ,  Allen Radin ,  Steven Weinstein ,  Denise Calaprice ,  Margaret Karow ,  Joanne Papadopoulos

IPC: A61K39/00 ,  C07K14/715

CPC classification number: C07H21/04 ,  A61K38/00 ,  C07K14/715 ,  C07K14/7155 ,  C07K16/244 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30 ,  C07K2319/32

Abstract: Methods of treating, inhibiting, or ameliorating arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, or juvenile rheumatoid arthritis, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein arthritis inhibited, or ameliorated. The IL-1 antagonist is an IL-1-specific fusion protein comprising an IL-1 binding portion of the extracellular domain of human II-1RAcP, an IL-1 binding portion of the extracellular domain of human IL-1RI, and a multimerizing component antagonist, preferably comprising a sequence selected from the group consisting of SEQ ID NO:4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, or a substantially identical sequence.

Abstract translation: 在有需要的人类受试者中治疗，抑制或改善关节炎，包括类风湿性关节炎，骨关节炎，银屑病关节炎，强直性脊柱炎或幼年型类风湿性关节炎的方法，包括向需要治疗的受试者施用治疗量的白介素1（ IL-1）拮抗剂，其中关节炎被抑制或改善。 IL-1拮抗剂是IL-1特异性融合蛋白，其包含人II-1RAcP的细胞外结构域的IL-1结合部分，人IL-1RI细胞外结构域的IL-1结合部分和多聚化 优选包含选自SEQ ID NO：4,6,8,10,12,14,16,18,20,22,24,26的序列，或基本相同的序列。